A New Era in Hereditary Angioedema Treatment: Sebetralstat Receives FDA Approval
Hereditary angioedema (HAE) – a rare,potentially life-threatening genetic condition causing episodes of severe swelling – is poised for a significant shift in treatment thanks to the recent FDA approval of sebetralstat,an oral plasma kallikrein inhibitor developed by KalVista Pharmaceuticals. This marks a pivotal moment for the estimated 6,000-10,000 individuals in the US living with HAE, offering a new option for on-demand attack management.
Understanding the breakthrough: How Sebetralstat Works
Sebetralstat represents a novel approach to HAE treatment. Unlike many existing therapies that focus on either preventing attacks or managing symptoms after they begin, sebetralstat directly inhibits plasma kallikrein, a key enzyme driving the inflammatory cascade responsible for HAE swelling. By blocking this enzyme, the medication aims to halt attacks in their earliest stages, offering patients greater control over their condition. This is akin to stopping a leak at its source, rather than simply mopping up the water.
The drug has already garnered significant recognition from the FDA, receiving both Fast Track and Orphan Drug designations, highlighting the unmet medical need it addresses. The New Drug Application (NDA) was accepted for review in September 2024,culminating in the recent approval.
Examining the Clinical Evidence: The Confident and Confident-S Trials
The FDA’s decision was largely based on compelling data from the Confident Phase III clinical trial. This crossover study evaluated the efficacy and safety of sebetralstat in adolescents and adults experiencing HAE attacks. Participants demonstrated a significant ability to effectively treat attacks with the oral medication. (ClinicalTrials.gov ID: Nct05259917).
Further bolstering the data is the ongoing Confident-S open-label extension trial (ClinicalTrials.gov ID: NCT05505916), designed to assess the long-term safety profile of sebetralstat. Currently estimated for completion in June 2026, this trial will provide valuable insights into the medication’s sustained effects and potential long-term benefits.
Key Trial Details:
Confident Trial: Focused on immediate attack efficacy and safety.
Confident-S Trial: Evaluating long-term safety and tolerability.
* Sponsor: KalVista Pharmaceuticals, Ltd.
The Impact on Patients: A Paradigm Shift in HAE Management
The approval of sebetralstat is more than just a new drug; it represents a fundamental change in how individuals with HAE can manage their condition. Previously, many patients relied on injectable therapies or intravenous infusions, requiring them to carry medication and potentially seek medical assistance during an attack. Sebetralstat’s oral formulation offers a convenient, discreet, and readily available treatment option, empowering patients to address symptoms as soon as they arise, nonetheless of location.
Ben Palleiko, CEO of KalVista, emphasized the importance of this advancement, stating that sebetralstat “enables people to treat attacks the moment symptoms begin, wherever they are.” He further envisions the drug becoming a foundational treatment for HAE, prioritizing access for those who need it most.1
Looking ahead: Accessibility and Future Research
While the FDA approval is a major milestone, ensuring broad access to sebetralstat remains a critical next step. KalVista is now focused on commercializing the drug and working with healthcare providers and insurance companies to facilitate patient access.
Furthermore, ongoing research will continue to explore the full potential of sebetralstat, including its potential role in combination therapies and its effectiveness across diverse patient populations. The HAE community eagerly anticipates the long-term impact of this innovative treatment on the lives of those affected by this challenging condition.
1 Source: [Original News Release – Replace with actual source link when available]
2 Source: [Original FDA Acceptance Information – Replace with actual source link when available]
New Oral Therapy Offers Rapid relief for Hereditary Angioedema
Hereditary Angioedema (HAE) is a rare, potentially life-threatening genetic condition characterized by unpredictable swelling attacks affecting various body parts. For years, treatment options have been limited to injectable therapies, often requiring patients to visit emergency rooms or administer medication themselves. However, a significant advancement in HAE management has arrived with the approval of a novel oral medication, sebetralstat, marketed as EKTERLY®.this marks the first time individuals with HAE have access to an on-demand oral treatment, promising greater convenience and control over their condition.
understanding the Burden of HAE
Approximately 1 in 50,000 people worldwide are estimated to live with HAE. While the condition is often invisible between attacks, the unpredictable nature of swelling – which can occur in the face, throat, abdomen, and limbs – substantially impacts quality of life. Swelling in the airway can be notably dangerous, potentially leading to asphyxiation. Historically, managing HAE has been akin to navigating a storm without a reliable lighthouse; patients often felt helpless as attacks unfolded, relying on reactive measures rather than proactive intervention.
KONFIDENT Trial Demonstrates Efficacy
The approval of EKTERLY® is based on the robust findings of the KONFIDENT clinical trial. this study involved patients receiving either 300mg or 600mg of sebetralstat, or a placebo, for up to two doses and treatment of up to three attacks. Results revealed a statistically significant reduction in the time to symptom relief with both sebetralstat dosages compared to placebo. Specifically, median times to symptom relief were approximately 1.61 and 1.79 hours for the 300mg and 600mg doses, respectively, a dramatic improvement over the 6.72 hours observed with the placebo.
Furthermore, the trial demonstrated faster resolution of attack severity.Patients treated with sebetralstat experienced a reduction in attack severity more quickly than those receiving a placebo (P =.004 and P = .003 for the 300mg and 600mg doses, respectively). Complete resolution of attacks within 24 hours was also notably higher in the sebetralstat groups – approximately 42.5% and 49.5% for the 300mg and 600mg doses, compared to just 27.4% with the placebo. This translates to a potentially significant decrease in the disruption attacks cause to daily life.
Long-Term Data from the KONFIDENT-S Extension Study
Building on the initial KONFIDENT results, the KONFIDENT-S extension trial provided valuable long-term safety and efficacy data. This open-label study confirmed the consistent safety profile of sebetralstat and highlighted its potential to empower patients to proactively manage their attacks.Participants in KONFIDENT-S initiated treatment a median of just 9 minutes after the onset of symptoms, demonstrating the convenience and accessibility of an oral on-demand therapy. The median time to symptom relief for laryngeal attacks (swelling in the throat) was approximately 1.3 hours.
A Paradigm Shift in HAE Management
The introduction of EKTERLY® represents a significant step forward in HAE care. As Dr. Marc A. Riedl, a leading investigator in the KONFIDENT trials, stated, “This is an significant moment for patients, giving people living with HAE a treatment option that could provide greater independence and control over managing their condition.”
Previously, on-demand treatments often required immediate injection, potentially delaying intervention while patients prepared and administered the medication. An oral formulation eliminates this barrier, allowing individuals to address attacks swiftly and discreetly, much like taking a pain reliever for a headache. This aligns with current treatment guidelines emphasizing early intervention to minimize attack severity and duration, ultimately improving the overall quality of life for those living with HAE. Importantly, clinical trials have shown a comparable safety profile to existing treatments, with no serious adverse events linked to the medication.
REFERENCES
- KalVista. KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema. News release. July 7, 2025. Accessed July 7, 2025. https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-fda-
## A New Era in Hereditary Angioedema Management: Sebetralstat’s FDA Acceptance
Hereditary Angioedema (HAE) is a rare,potentially life-threatening genetic condition characterized by recurrent episodes of swelling in various parts of the body. Traditionally, managing these attacks has involved inconvenient and often costly treatments. However, recent advancements offer a promising new avenue for patients seeking rapid relief. The Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for sebetralstat, an oral, on-demand medication developed by KalVista Pharmaceuticals, signaling a potential paradigm shift in HAE treatment [[2]].### Understanding Hereditary Angioedema and the Need for Novel Therapies
HAE affects an estimated 1 in 50,000 individuals globally. The condition stems from a deficiency or dysfunction of the C1 inhibitor protein,leading to excessive bradykinin production,a potent inflammatory mediator. This results in swelling that can occur in the skin, gastrointestinal tract, and even the airways, posing a serious risk of asphyxiation